Immune Design Corp (NASDAQ:IMDZ) major shareholder Leo Guthart purchased 20,000 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were purchased at an average price of $3.90 per share, with a total value of $78,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Leo Guthart also recently made the following trade(s):
- On Friday, October 27th, Leo Guthart purchased 2,439,000 shares of Immune Design stock. The shares were purchased at an average price of $4.10 per share, with a total value of $9,999,900.00.
- On Tuesday, October 24th, Leo Guthart acquired 60,000 shares of Immune Design stock. The shares were bought at an average cost of $4.65 per share, with a total value of $279,000.00.
- On Thursday, October 19th, Leo Guthart acquired 10,000 shares of Immune Design stock. The shares were bought at an average cost of $6.09 per share, with a total value of $60,900.00.
Shares of Immune Design Corp (NASDAQ:IMDZ) traded down $0.05 on Friday, hitting $3.20. 642,224 shares of the stock were exchanged, compared to its average volume of 564,320. Immune Design Corp has a 1-year low of $2.94 and a 1-year high of $13.05. The firm has a market capitalization of $153.79, a price-to-earnings ratio of -1.50 and a beta of 2.03.
Immune Design (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.62 million. research analysts predict that Immune Design Corp will post -1.89 EPS for the current year.
A number of large investors have recently bought and sold shares of IMDZ. Bain Capital Public Equity Management LLC raised its position in Immune Design by 393.1% in the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock worth $3,797,000 after purchasing an additional 310,433 shares in the last quarter. JPMorgan Chase & Co. raised its position in Immune Design by 118.7% in the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock worth $5,175,000 after purchasing an additional 288,009 shares in the last quarter. Sectoral Asset Management Inc acquired a new position in Immune Design in the second quarter worth about $1,641,000. Numeric Investors LLC acquired a new position in Immune Design in the second quarter worth about $1,641,000. Finally, Vanguard Group Inc. raised its position in Immune Design by 37.9% in the second quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after purchasing an additional 144,408 shares in the last quarter. 29.38% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have recently commented on IMDZ shares. Wells Fargo & Co lowered shares of Immune Design from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $29.00 to $10.00 in a research report on Tuesday, October 17th. ValuEngine lowered shares of Immune Design from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Cowen reaffirmed a “buy” rating on shares of Immune Design in a research report on Monday, December 11th. Finally, Zacks Investment Research raised shares of Immune Design from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $13.06.
COPYRIGHT VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/02/immune-design-corp-imdz-major-shareholder-leo-guthart-buys-20000-shares-of-stock.html.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.